Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells

T-VEC, a HSV-1 derived oncolytic virus, is approved for the treatment of advanced melanoma. The mechanisms that underly the systemic anti-tumor effect that is seen following intratumoral injection have not yet been studied but are likely to be mediated by myeloid dendritic cells (myDC) that initiate...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Jens Tijtgat, Jolien De Munck, Inès Dufait, Julia Katharina Schwarze, Ivan Van Riet, Lorenzo Franceschini, Karine Breckpot, Joeri L. Aerts, Bart Neyns, Sandra Tuyaerts
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Frontiers Media S.A. 2021-10-01
Σειρά:	Frontiers in Immunology
Θέματα:	melanoma myeloid dendritic cell BDCA-1 BDCA-3 Talimogene laherparepvec cell therapy
Διαθέσιμο Online:	https://www.frontiersin.org/articles/10.3389/fimmu.2021.733506/full
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!